Research
Metabolic adaptation
Semaglutide add-on to metformin significantly decreases the Visceral Adiposity Index (VAI) in type 2 diabetic patients, with the greatest reduction in the obesity group (-0.70).
Incorporating semaglutide with metformin may enhance fat loss in patients with type 2 diabetes, especially those with obesity.
StrongSupportsmedium confidence
VAI showed minimal changes with metformin alone but decreased significantly with semaglutide add-on (p < 0.05), with the greatest reduction in the obesity group (-0.70).
Why this rating
The study involves a controlled trial with a defined patient population.
Source
Effect of Semaglutide Add-on to Metformin on Visceral Adiposity Index and Markers of Visceral Adipose Tissue Activity in Type 2 Diabetic Patients
Abid Shaheer et al. · Biomedical & Pharmacology Journal · 2025
other · n=90Cited 1×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →